IRs and HRs for major bleeding and thrombosis
| . | Bleeding events . | Thrombotic events . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of events . | Person-years . | IR* . | 95% CI . | HR† . | 95% CI . | P . | No. of events . | Person-years . | IR* . | 95%CI . | HR† . | 95%CI . | P . | |
| Overall | 13 | 3699.9 | 3.5 | 2.0-6.1 | 28 | 3663.8 | 7.6 | 5.3-11.1 | ||||||
| Restricted to adults (≥18 y) | 12 | 1984 | 6.0 | 3.4-10.7 | 27 | 1949.4 | 13.9 | 9.5-2.2 | ||||||
| Relatives | 2 | 1064.5 | 1.9 | 0.5-7.5 | 1.0 (ref) | 6 | 1038.8 | 5.8 | 2.6-12.9 | 1.0 (ref) | ||||
| Propositi | 11 | 2635.4 | 4.2 | 2.3-7.5 | 2.1 | 0.5-9.6 | .33 | 22 | 2625 | 8.4 | 5.5-12.7 | 1.1 | 0.4-2.7 | .86 |
| Men | 3 | 1281.9 | 2.3 | 0.8-7.3 | 1.0 (ref) | 11 | 1192.3 | 9.2 | 5.1-16.7 | 1.0 (ref) | ||||
| Women | 10 | 2418 | 4.1 | 0.2-7.7 | 1.8 | 0.5-6.5 | .39 | 17 | 2471.5 | 6.9 | 4.3-11.1 | .9 | 0.4-1.9 | .72 |
| Nonhotspot mutations‡ | 4 | 1085.8 | 3.7 | 1.4-9.8 | 1.0 (ref) | 9 | 1090.8 | 8.3 | 4.3-15.9 | 1.0 (ref) | ||||
| FGA Arg35 | 2 | 818.2 | 2.4 | 0.6-9.8 | 0.8 | 0.1-4.1 | .74 | 5 | 809 | 6.2 | 2.6-14.8 | .8 | 0.3-2.4 | .68 |
| FGG Arg301 | 7 | 1795.9 | 3.9 | 1.9-8.2 | 1.2 | 0.4-4.1 | .79 | 14 | 1763.9 | 7.9 | 4.7-13.4 | 1.1 | 0.5-2.6 | .83 |
| Until diagnosis of CD | 11 | 2896.9 | 3.8 | 2.1-6.9 | 1.0 (ref) | 14 | 2955.6 | 4.7 | 2.8-8.0 | 1.0 (ref) | ||||
| After diagnosis of CD | 2 | 803.1 | 2.5 | 0.6-10.0 | 0.5 | 0.1-2.6 | .45 | 14 | 748 | 18.7 | 11.0-31.6 | 2.0 | 0.9-4.7 | .1 |
| . | Bleeding events . | Thrombotic events . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of events . | Person-years . | IR* . | 95% CI . | HR† . | 95% CI . | P . | No. of events . | Person-years . | IR* . | 95%CI . | HR† . | 95%CI . | P . | |
| Overall | 13 | 3699.9 | 3.5 | 2.0-6.1 | 28 | 3663.8 | 7.6 | 5.3-11.1 | ||||||
| Restricted to adults (≥18 y) | 12 | 1984 | 6.0 | 3.4-10.7 | 27 | 1949.4 | 13.9 | 9.5-2.2 | ||||||
| Relatives | 2 | 1064.5 | 1.9 | 0.5-7.5 | 1.0 (ref) | 6 | 1038.8 | 5.8 | 2.6-12.9 | 1.0 (ref) | ||||
| Propositi | 11 | 2635.4 | 4.2 | 2.3-7.5 | 2.1 | 0.5-9.6 | .33 | 22 | 2625 | 8.4 | 5.5-12.7 | 1.1 | 0.4-2.7 | .86 |
| Men | 3 | 1281.9 | 2.3 | 0.8-7.3 | 1.0 (ref) | 11 | 1192.3 | 9.2 | 5.1-16.7 | 1.0 (ref) | ||||
| Women | 10 | 2418 | 4.1 | 0.2-7.7 | 1.8 | 0.5-6.5 | .39 | 17 | 2471.5 | 6.9 | 4.3-11.1 | .9 | 0.4-1.9 | .72 |
| Nonhotspot mutations‡ | 4 | 1085.8 | 3.7 | 1.4-9.8 | 1.0 (ref) | 9 | 1090.8 | 8.3 | 4.3-15.9 | 1.0 (ref) | ||||
| FGA Arg35 | 2 | 818.2 | 2.4 | 0.6-9.8 | 0.8 | 0.1-4.1 | .74 | 5 | 809 | 6.2 | 2.6-14.8 | .8 | 0.3-2.4 | .68 |
| FGG Arg301 | 7 | 1795.9 | 3.9 | 1.9-8.2 | 1.2 | 0.4-4.1 | .79 | 14 | 1763.9 | 7.9 | 4.7-13.4 | 1.1 | 0.5-2.6 | .83 |
| Until diagnosis of CD | 11 | 2896.9 | 3.8 | 2.1-6.9 | 1.0 (ref) | 14 | 2955.6 | 4.7 | 2.8-8.0 | 1.0 (ref) | ||||
| After diagnosis of CD | 2 | 803.1 | 2.5 | 0.6-10.0 | 0.5 | 0.1-2.6 | .45 | 14 | 748 | 18.7 | 11.0-31.6 | 2.0 | 0.9-4.7 | .1 |